ABVCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ECOC
ABVC BIOPHARMA, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.91−0.01 (-0.86%)
Close on Oct 19, 2026
- Market cap
- $23.71M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$2.0100 (−68.84%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
ABVC BIOPHARMA, INC. grew revenue 0.0% to $296.00K over fiscal 2025.
Revenue
$296.00K
0.0% vs. a year earlier
Operating income
-$6.52M
TTM Q2 2026
EPS, diluted
-$0.39
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $23.71M
- P/E ratio
- –
- Price to sales
- 80.11
- Price to book
- 2.31
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $296.00K
- Net income
- -$7.11M
- EPS, diluted
- -$0.39
- Book value per share
- $0.39
- Diluted shares
- 26M
Fifteen years at a glance
Fiscal years 2010 to 2025 and trailing twelve months, USD
Revenue
–
Gross profit
–
Operating income
-$6.52M
Net income
-$7.11M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months